Lin Shilan, Chen Zhijie, Li Shaoguang, Chen Bing, Wu Youjia, Zheng Yanjie, Huang Jianyong, Chen Yan, Lin Xinhua, Yao Hong
Department of Pharmaceutical Analysis, School of Pharmacy, Fujian Medical University, Fuzhou, China.
Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, 350001, China.
Heliyon. 2024 Jan 17;10(2):e24778. doi: 10.1016/j.heliyon.2024.e24778. eCollection 2024 Jan 30.
In this study, the therapeutic effect and possible mechanism of the total biflavonoid extract of Hieron (SDTBE) against cervical cancer were originally investigated in vitro and in vivo. First, the inhibition of SDTBE on proliferation of cervical cancer HeLa cells was evaluated, followed by morphological observation with AO/EB staining, Annexin V/PI assay, and autophagic flux monitoring to evaluate the possible effect of SDTBE on cell apoptosis and autophagy. Cell cycle, as well as mitochondrial membrane potential (Δ), was detected with flow cytometry. Further, the apoptosis related protein expression and the autophagy related gene LC3 mRNA transcription level were analyzed by Western blot (WB) and real-time quantitative polymerase chain reaction (RT-qPCR), respectively. Finally, the anti-cervical cancer effect of the SDTBE was also validated in vivo in HeLa cells grafts mice. As results, SDTBE inhibited HeLa cells proliferation with the IC values of 49.05 ± 6.76 and 44.14 ± 4.75 μg/mL for 48 and 72 h treatment, respectively. The extract caused mitochondrial ΔѰ loss, induced cell apoptosis by upregulating Bax, downregulating Bcl-2, activating Caspase-9 and Caspase-3, promoting cell autophagy and blocking the cell cycle in G0/G1 phase. Furthermore, 100, 200, and 300 mg/kg SDTBE suppressed the growth of HeLa cells xenografts in mice with the mean inhibition rates, 25.3 %, 57.5 % and 62.9 %, respectively, and the change of apoptosis related proteins and microvascular density was confirmed in xenografts by immunohistochemistry analysis. The results show that SDTBE possesses anti-cervical cancer effect, and the mechanism involves in activating Caspase-dependent mitochondrial apoptosis pathway.
本研究首次在体外和体内研究了希俄斯岛乳香(SDTBE)总双黄酮提取物抗宫颈癌的治疗效果及可能机制。首先,评估SDTBE对宫颈癌HeLa细胞增殖的抑制作用,随后采用AO/EB染色、Annexin V/PI检测及自噬通量监测进行形态学观察,以评估SDTBE对细胞凋亡和自噬的可能影响。通过流式细胞术检测细胞周期以及线粒体膜电位(Δ)。此外,分别通过蛋白质免疫印迹法(WB)和实时定量聚合酶链反应(RT-qPCR)分析凋亡相关蛋白表达和自噬相关基因LC3 mRNA转录水平。最后,还在HeLa细胞移植瘤小鼠体内验证了SDTBE的抗宫颈癌作用。结果显示,SDTBE抑制HeLa细胞增殖,48 h和72 h处理的IC值分别为49.05±6.76和44.14±4.75 μg/mL。该提取物导致线粒体ΔѰ丧失,通过上调Bax、下调Bcl-2、激活Caspase-9和Caspase-3诱导细胞凋亡,促进细胞自噬并使细胞周期阻滞在G0/G1期。此外,100、200和300 mg/kg SDTBE抑制小鼠体内HeLa细胞移植瘤生长,平均抑制率分别为25.3%、57.5%和62.9%,免疫组化分析证实移植瘤中凋亡相关蛋白和微血管密度发生变化。结果表明,SDTBE具有抗宫颈癌作用,其机制涉及激活Caspase依赖的线粒体凋亡途径。